{"id":82803,"date":"2021-09-15T12:20:37","date_gmt":"2021-09-15T07:50:37","guid":{"rendered":"https:\/\/aprinpharmed.com\/hynic-toc-trifluoroacetate\/"},"modified":"2023-02-09T09:04:05","modified_gmt":"2023-02-09T05:34:05","slug":"hynic-toc-trifluoroacetate","status":"publish","type":"page","link":"https:\/\/aprinpharmed.com\/en\/hynic-toc-trifluoroacetate\/","title":{"rendered":"HYNIC-TOC"},"content":{"rendered":"

[vc_row][vc_column]

Aprin Pharmed<\/div>
_<\/span>

HYNIC-TOC<\/span><\/p>\n

 <\/p>\n

HYNIC-TOC is a peptide radiopharmaceutical consisting of two parts, an octreotide-like peptide chain and a chelating agent called HYNIC that binds to somatostatin receptors on the surface of cancer tumors. Additionally, it is used in the diagnosis and monitoring of neuroendocrine malignancies, most of which are found in the bowel, pancreas, or lungs.<\/p>\n

.<\/p>\n

\"\"<\/p>\n<\/div>_<\/span><\/div><\/div>[\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row][vc_column width=”1\/6″][\/vc_column][vc_column width=”2\/3″]
CAS registration number<\/div><\/span>
  • <\/i><\/div>
    257943-19-4<\/span><\/div><\/li><\/ul><\/div><\/div>
    molecular mass<\/div><\/span>
    • <\/i><\/div>
      1284.38 \u06af\u0631\u0645 \u0628\u0631 \u0645\u0648\u0644<\/span><\/div><\/li><\/ul><\/div><\/div>
      Molecular formula<\/div><\/span>
      • <\/i><\/div>
        C55H71N13O12S2.C2HF3O2 <\/span><\/div><\/li><\/ul><\/div><\/div>
        Appearance<\/div><\/span>
        • <\/i><\/div>
          white powder<\/span><\/div><\/li><\/ul><\/div><\/div>
          synonym<\/div><\/span>
          • <\/i><\/div>
            HYNIC-[Tyr3] Octreotide<\/span><\/div><\/li><\/ul><\/div><\/div>
            Peptide sequence<\/div><\/span>
            • <\/i><\/div>
              Hynic-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OL (Disulfide Bridge Cys2-Cys7)<\/span><\/div><\/li><\/ul><\/div><\/div>
              Maintenance<\/div><\/span>
              • <\/i><\/div>
                2-8 degrees Celsius<\/span><\/div><\/li><\/ul><\/div><\/div>
                Therapeutic applications<\/div><\/span>
                • <\/i><\/div>
                  Positron Emission Tomography (PET) imaging or radionuclide therapy<\/span><\/div><\/li><\/ul><\/div><\/div><\/div><\/div>[\/vc_column][vc_column width=”1\/6″][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"

                  [vc_row][vc_column][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/6″][\/vc_column][vc_column width=”2\/3″][\/vc_column][vc_column width=”1\/6″][\/vc_column][\/vc_row] … <\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-82803","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/82803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/comments?post=82803"}],"version-history":[{"count":11,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/82803\/revisions"}],"predecessor-version":[{"id":83266,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/82803\/revisions\/83266"}],"wp:attachment":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/media?parent=82803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}